Introduction
Combined oral contraceptives (COCs) reduce circulating androgen levels by inhibition of ovarian and adrenal androgen synthesis. In particular, the level of testosterone (T), the most potent female androgen, decreases by a mean of 31% [1] . In addition, the estrogenic component of COCs, ethinylestradiol (EE), stimulates hepatic sex hormone-binding globulin (SHBG) production considerably in a dose-dependent manner [1] . Because SHBG binds and inactivates T, there is further suppression of the free T concentrations (up to 61%) and the free androgen or T index (FAI or FTI), a measure of bioavailable T, is significantly reduced [1, 2] .
T deficiency in women has been associated with a broad range of undesired effects [3, 4] , some of which, including mood disturbances and interference with sexual function, have been reported as side effects of COCs [5] [6] [7] [8] . Normalizing total T and other androgen levels in women using a COC may be achieved by the co-administration of the natural human adrenal androgen dehydroepiandrosterone (DHEA), because it is orally bioavailable [9] and partially metabolized into T [10] [11] [12] .
In the present prospective study the effect of daily co-administration of 50 mg DHEA in new COC users was investigated. In this paper the effect on androgen and androgenrelated endocrine parameters will be reported. In a second paper the clinical effects on sexual function, mood, skin and safety will be reported [13] . M A N U S C R I P T
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Materials and Methods
Study population
Participants had to be healthy, sexually active, aged between 18 and 35 years, and have a body mass index (BMI) between 18 and 35 kg/m 2 . All participants must not have taken a
hormonal contraceptive for at least 3 months prior to the start of the study medication. In addition, subjects were required to have a regular menstrual cycle of 25-35 days before the start of the study. Major exclusion criteria were contraindications for COC use; concomitant medication that might interfere with the metabolism of contraceptive steroids or DHEA;
hyperandrogenism (free T levels ≥ 31.0 pmol/L), severe acne, severe hirsutism and polycystic ovarian syndrome based on ovarian ultrasound and/or the LH/FSH ratio.
The study was approved by an independent ethics committee and was conducted in accordance with the Declaration of Helsinki and the ICH guideline for Good Clinical
Practice. All participants gave written informed consent. The study has been registered at the International Standard Randomised Controlled Trial Number Register (no.
ISRCTN06414473).
Study design and procedures
This randomized, double-blind, placebo-controlled, comparative, parallel-group study was conducted from November 2007 until November 2009 at the University Hospital
Centre Hospitalier Régional (CHR) Citadelle, in Liège, Belgium. Prior to randomization, evidence of ovulation during a spontaneous menstrual cycle was documented by a midluteal progesterone level of >4.77 nmol/L (1.5 ng/mL). Eligible participants were randomized to a 30 µg EE and 3 mg drospirenone (DRSP) COC with co-administration of DHEA or placebo in a ratio of 1:1. Although all COCs suppress androgens [1] , the EE/DRSP COC was chosen,
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Europe [14] . Blinded study medication was packed per subject number according to a computer-generated randomization list that was only known to an independent biostatistician.
The study consisted of a 3 cycle run-in period with COC use alone, followed by a 6 cycle treatment period in which participants continued COC use in combination with either DHEA or a placebo. Each treatment cycle consisted of 28 days. During all treatment cycles participants took one tablet of the EE/DRSP COC from day 1 to day 21 followed by a pillfree period of 7 days. During the 6-cycle treatment period, DHEA or placebo was used continuously, including during the pill-free period.
Study visits took place before the start of the COC during the luteal phase of the cycle (baseline), once every three cycles thereafter on cycle days 22-28 (cycle 3, cycle 6 and cycle 9) and at a follow-up 7-14 days after the last intake of study medication. During these visits, blood samples were taken in the morning after an overnight fasting period before administration of study medication.
The primary endpoint was the change in total T levels between the end of the run-in treatment period (cycle 3) and the end of the treatment period (cycle 9). Secondary objectives included the change in the following laboratory parameters during COC use only (baseline to end of the run-in period at cycle 3) and during the treatment period (end of the run-in period to cycle 6 and cycle 9): Total T, albumin, SHBG, free T, FTI, DHEA-sulfate (DHEA-S), 4-androstenedione (AD), 3α-androstanediol glucuronide (ADG) and estradiol (E 2 ).
Study medication
A dose of 50 mg DHEA was calculated to compensate for the loss of T induced by a COC, based on previous dose-finding studies with DHEA in elderly people [10] , along with the magnitude of the decrease of T levels during COC use [1] . The DHEA and placebo tablets
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AMUSA I Endo Tables 18 July were manufactured by Unither Pharmaceuticals (Le Haillan, France) and were identical in appearance. The commercially available COC Yasmin ® (Bayer Healthcare, Berlin) was used. Analysis of albumin was performed by an automated bromocresol green method on Modular system. The intra-and inter-assay coefficients of variance for the assays are shown in Supplemental Table 1 .
Analytical assays and measurements
Free T (pmol/L) was calculated based on total T, SHBG and albumin (g/L)
concentrations [15, 16] . The FTI (or FAI)) was calculated using total T and SHBG, according to the formula: FTI = 100 x [T]/[SHBG].
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Statistical analysis
A sample size calculation was carried out, which was based on the primary objective of the study to test the null hypothesis that 50 mg DHEA added to an EE/DRSP COC is able to significantly increase total T levels from the end of the run-in period to the end of the treatment period compared to placebo. Assuming that T levels would decline by at least one third of their value (33%) at the end of the run-in-period, that initial T levels would be completely restored (100%) after 6 cycles in the DHEA group and remain unchanged in the placebo group, at the 5% significance level and with a power of 90%, 37 participants were to be needed in each group to demonstrate a difference (total 74). Considering a 30% adjustment of sample sizes due to discontinuation and non-evaluable cycles, a minimum of 96 women were to be included in the study. Therefore, it was decided to randomize in total 100
participants (50 per treatment group).
Data analyses were based on an intention to treat approach. A log-transform was used to normalize the distribution of the variables if necessary. Within each treatment group (DHEA and placebo), changes between study visits were assessed for each variable using a paired t-test. When comparing these changes between the two groups (DHEA vs placebo), the unpaired t-test with unequal variances was used. Results were considered to be significant at the 5% level (P < 0.05). All calculations were carried out using SAS (Version 9.1 for Windows) and S-PLUS (Version 7.0) statistical packages. M A N U S C R I P T
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Results
Study population characteristics
A total of 142 women were screened, of which 99 were randomized and treated. The baseline characteristics of the study population were comparable between groups (Table 1) . Only two women, both in the placebo group, discontinued early ( Figure 1 ), one after 6 cycles for logistical reasons and one after 4 cycles at her own initiative because of hirsutism. All available data were included in the analyses.
Endocrine parameters
The effect of COC use alone on androgens and parameters related to androgen metabolism during the run-in period are shown in Table 2 . At the end of the run-in period, a statistically significant decline of 62% was found for total T (P < 0.0001) ( Table 2 and Figure 2) . A large and statistically significant decrease of free T (86%) and the FTI (91%) was also observed (both P < 0.0001) ( Table 2 and Figure 2 ). SHBG levels increased significantly (243%; P < 0.0001) ( Table 2 and Figure 2 ). COC use alone resulted in statistically significant decreases in all the other parameters ( Table 2 ).
The effect of 50 mg DHEA plus COC compared to placebo plus COC on androgens and parameters related to androgen metabolism is shown in Table 2 . Total T significantly increased in the DHEA group compared to the placebo group (change from end of run-in period to end of treatment period: 1.3±1.2 vs 0.0±0.4 nmol/L; P < 0.0001) ( Table 2 and Figure 2 ). Statistically significant increases from the end of the run-in period to the end of the treatment period in the DHEA compared to the placebo group were also observed for free T, the FTI, DHEA-S, AD and ADG (Table 2 ; P < 0.0001 for each). The change from the end of
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The change and the relative change from baseline to the end of the treatment period is also shown in Table 2 . Total T levels were restored to baseline levels in the DHEA group and remained low in the placebo group; the levels were significantly increased from baseline to the end of the treatment period in the DHEA group compared to placebo (0.3 nmol/L [relative change: 20%] vs -0.8 nmol/L [-52%]; P < 0.0001) ( Table 2 and Figure 2 ). In the placebo group the free T levels and the FTI remained as low as at baseline and in the DHEA group they were still lower than at baseline, but were statistically higher than placebo (Free T Figure 2 ). DHEA-S, AD and ADG levels were restored to levels above baseline in the DHEA group but not in the placebo group (between group difference P < 0.0001 for each; Table 2 ).
There were no statistically significant between group differences for albumin and E 2 ; albumin levels remained relatively unchanged in both groups (relative change: -5% and -6%) and E 2 levels decreased from baseline in both groups (-75% and -71%).
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Discussion
To our knowledge this is the first study aiming at restoring the levels of T during COC use.
For this purpose we could have used e.g. a T-gel or a T-patch, but we have chosen to try to achieve normalization of T levels by daily co-administration of the oral T-precursor DHEA, since our goal is to develop a new oral contraceptive combination.
The study was designed to create optimal conditions to evaluate first the effect of a COC only. Therefore only women who had not used hormonal contraception for at least 3 months were included in the study and there was a 3-cycle run-in period with COC use alone prior to the DHEA/placebo treatment period. The observed qualitative changes of the (precursor) androgens and SHBG after COC use alone are in agreement with previous studies [1, 2, [17] [18] [19] [20] [21] , but the quantitative suppression of total T and free T by 62% and 86%, respectively is more pronounced than reported in the literature previously (mean of 31% and 61%, respectively) [1] . Importantly, all COC users experienced a decrease of their total and free T.
By administering 50 mg/day DHEA total T was restored completely to baseline levels. However the decrease of the biologically active free T levels was restored by only 47%. We hypothesize that this is caused by the increased binding of T due to the strong rise of SHBG (243%) caused by the COC. The progestin DRSP does not counteract the effect of the estrogen (EE) on SHBG and may even increase SHBG further due to its anti-androgenic properties. Also the radioimmunoassay used to measure total T itself may be sensitive to high SHBG levels [22] . Levels of total T, as well as its measurement, are critically influenced by the concomitant rise of SHBG, which occurs with most, but not all COCs; therefore total T levels during COC use may be unreliable to judge the androgen status. Studies aiming at restoration of T homeostasis during COC use need to take these issues into account [22] .
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Although androgens including DHEA are known to decrease SHBG [23, 24] , in the current study no significant decrease of SHBG was observed in the DHEA group, which may be due to the relatively low 50 mg dose of DHEA used. The precursor androgens DHEA-S, AD and ADG were restored to levels above baseline. This is not considered to be clinically relevant since these circulating androgen precursors are biologically inactive [25] . Overall, to normalize free T completely when using a DRSP containing COC, a higher dose of DHEA may be required.
Accurate measurement of free T in blood of females is difficult [26, 27] due to the very low concentrations (35 -700 pmol/L; [24] ), especially in women using COCs [1] .
Preferred methods for direct measurement of free T are the mass action equation and equilibrium dialysis [3, 28] . These methods are time-consuming and have several drawbacks, such as requirement of a large volume sample, dilution effects, complicated correction of volume changes and inherent limitations of tracer analog method [29] . Furthermore, the detection level of the available LC-MS/MS method was not low enough. Therefore, in this study free T was obtained by calculation based on total T, SHBG and albumin concentrations [15, 16] , which has previously been demonstrated to be a reliable method and comparable to direct measurements [28, 30] .
A small but significant lowering of albumin by COC use only has been observed in some [2, 31] but not all [32] earlier studies. In the current study neither the COC use only nor the addition of DHEA affected albumin levels. Because COCs inhibit follicular development, E 2 levels decreased significantly during both treatments. Since oral DHEA is not only metabolized by the liver to T, but also to E 2 [33], it is important to note that E 2 levels did not increase with the low 50 mg dose of DHEA used in the current study.
In conclusion, this study shows that an EE/DRSP containing COC strongly suppresses endogenous androgen concentrations in all users. Total T levels were restored completely to
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